Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC).

J. Heymach; B. S. Glisson; R. C. Doebele; C. Huang; D. R. Gandara; S. Le Scouiller; M. A. Marotti; D. R. Camidge

doi:10.1200/jco.2010.28.15_suppl.7050

Phase I open-label study of cediranib plus etoposide (E) and cisplatin (P) as first-line therapy for patients (pts) with small cell lung cancer (SCLC) or lung neuroendocrine cancer (NEC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7050 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7050-7050 ◽

Cited By ~ 5

Author(s):

J. Heymach ◽

B. S. Glisson ◽

R. C. Doebele ◽

C. Huang ◽

D. R. Gandara ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Neuroendocrine Cancer ◽

First Line Therapy ◽

Line Therapy

Download Full-text

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000273 ◽

2014 ◽

Vol 9 (10) ◽

pp. 1532-1539 ◽

Cited By ~ 23

Author(s):

D. Ross Camidge ◽

Eamon M. Berge ◽

Robert C. Doebele ◽

Marc S. Ballas ◽

Thierry Jahan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

First Line Therapy ◽

Line Therapy

Download Full-text

A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.7588 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 7588-7588 ◽

Cited By ~ 15

Author(s):

D. R. Camidge ◽

M. S. Ballas ◽

S. Dubey ◽

M. Haigentz ◽

P. J. Rosen ◽

...

Keyword(s):

Lung Cancer ◽

Human Monoclonal Antibody ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Final Results of a Phase 2, Open-Label Study of Ramucirumab (IMC-1121B; RAM), an IGG1 MAB Targeting Vegfr-2, with Paclitaxel and Carboplatin as First-Line Therapy in Patients (PTS) with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) (NCT00735696)

Annals of Oncology ◽

10.1016/s0923-7534(20)33884-9 ◽

2012 ◽

Vol 23 ◽

pp. ix422-ix423

Author(s):

D.R. Camidge ◽

R.C. Doebele ◽

M. Ballas ◽

T. Jahan ◽

M. Haigentz ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70046-x ◽

2015 ◽

Vol 16 (3) ◽

pp. 328-337 ◽

Cited By ~ 75

Author(s):

Luis Paz-Ares ◽

Jörg Mezger ◽

Tudor E Ciuleanu ◽

Jürgen R Fischer ◽

Joachim von Pawel ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Therapy ◽

Line Therapy ◽

Randomised Controlled

Download Full-text

Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-016-1052-3 ◽

2016 ◽

Vol 22 (1) ◽

pp. 79-79 ◽

Cited By ~ 1

Author(s):

Noboru Yamamoto ◽

Koichi Goto ◽

Makoto Nishio ◽

Kenichi Chikamori ◽

Toyoaki Hida ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Egfr Mutation ◽

Japanese Patients ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

Cancer ◽

10.1002/cncr.29132 ◽

2014 ◽

Vol 121 (6) ◽

pp. 883-892 ◽

Cited By ~ 30

Author(s):

Robert C. Doebele ◽

David Spigel ◽

Mustapha Tehfe ◽

Sachdev Thomas ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Chemotherapy

Download Full-text

A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps8128 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS8128-TPS8128 ◽

Cited By ~ 4

Author(s):

David Paul Carbone ◽

Mark A. Socinski ◽

Allen C. Chen ◽

Prabhu Bhagavatheeswaran ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Stage Iv ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Trial

Download Full-text

P3-135: Results of an open-label, Phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab as first-line therapy in patients with advanced non-squamous non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000284110.26459.89 ◽

2007 ◽

Vol 2 (8) ◽

pp. S736-S737

Author(s):

Craig Reynolds ◽

David Barrera ◽

Duy Quoc Vu ◽

Robert Jotte ◽

Alexander I. Spira ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii Trial ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Phase

Download Full-text

168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1016/j.annonc.2021.10.187 ◽

2021 ◽

Vol 32 ◽

pp. S1456

Author(s):

B. Halmos ◽

P. Cobb ◽

M.L. Johnson ◽

L. Jain ◽

S.J. Kim ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text

A phase III, randomized, open-label, multicenter study of SHR-1210 (anti-PD-1 antibody) in combination with pemetrexed and carboplatin as first line therapy in subjects with advanced/metastatic non-squamous non-small cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdy292.126 ◽

2018 ◽

Vol 29 ◽

pp. viii545 ◽

Cited By ~ 1

Author(s):

F. Wu ◽

G. Gao ◽

C. Zhou ◽

X. Kang ◽

Y. Zhou

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Multicenter Study ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

First Line Therapy ◽

Line Therapy

Download Full-text